Our findings may be a clue for early onset of impairment in cognitive functions in cases with new onset diabetes during pregnancy.

Background:The causes of hospitalization may provide important information on the course of diseases and treatment-related adverse effects.Objectives:We aimed to determine the causes and outcome of hospitalizations among patients with Behçet Syndrome (BS) in a dedicated center.Methods:We surveyed hospitalization records in our clinic between January 2002 and December 2019 and identified those with a diagnosis of BS. The records of these patients were reviewed for demographic and clinical features, causes of hospitalization and outcome. We divided hospitalization causes into 2 as being BS related (organ involvement or deterioration) and non-BS related (treatment complication or others).Results:Three-hundred and thirty BS patients (75% men, mean age 37.7 ±11.4 SD years) were hospitalized for a total of 456 times during 18 years. The mean disease duration was 10.8± 8.8 SD years. Two-hundred and ninety-one (64%) patients were using immunosuppressives (IS) with or without corticosteroids (CSs) and 72 (16%) of them were under biologic treatment at the time of hospitalization. The mean duration of hospitalization was 12.7±10.7 SD days. The reasons for hospitalization were directly related to BS in 259 patients (57%) and non-related to BS in 191 (42%). Six patients were hospitalized for both BS and non-BS related reasons at the same time. The most common reasons were vascular involvement (n=169, 64%) for BS related reasons and infections (n=64, 32%) for non-BS related reasons (Table 1). Patients hospitalized for BS related causes were younger (35.2±10.6 vs 41.1±11.7, p<0.001), had short mean disease duration (8.5±7.5 vs. 13.6±9.4 years, p<0.001), stayed shorter in the hospital (11.6±8.6 vs 14.0±12.9 days p=0.03) and had less frequent IS±CSs use (59% vs 70%, p=0.02) compared to those with non-BS related hospitalizations. There were no differences between the groups regarding gender distribution (203 M/62 F vs. 143 M/54 F) and use of biologic agents (15% vs 17%). Three patients died during hospitalization. The reasons were malignancy, infection and right heart failure due to pulmonary artery thrombosis and pulmonary hypertension, respectively.Conclusion:Vascular involvement is the leading cause of hospitalization among BS patients, followed by infections. The predominance of men among hospitalized patients underlines the relatively severe course of BS in men. The retrospective design and inclusion of patients who were hospitalized only in the rheumatology unit are limitations of this study.Table 1.Distributions of BS related and non-BS related reasons of hospitalizationsBS patients hospitalized with BS related reasons(n of pts=195, n of hospitalizations=265)*BS patients hospitalized with non-BS related reasons(n of pts=170, n of hospitalizations=197)*Causes of hospitalizations (per hospitalization)Vascular inv. (n=169, 64 %)Pulmonary artery inv. (n=64, 24 %)Deep vein thrombosis (n=39, 15 %)Budd-Chiari synd. (n=24, 9%)Vena cava inf. thrombosis (n=19, 7 %)Peripheral artery inv. (n=15, 6 %)Vena cava sup. thrombosis (n=14, 5 %)Aorta inv. (n=14, 5%)Coronary artery inv. (n=4, 2 %)Infection (n=64, 32%)Pneumonia (n=17, 8%)Tuberculosis (n=8, 4%)Urinary tract inf (n=7, 4%)Gastroenteritis (n=4, 2%)Osteomyelitis (n=3, 2%)Septic arthritis (n=3, 2%)Aspergillosis (n=2, 1%)Nocardia (n=1, 1%)Salmonella (n=1, 1%)Others (n=18, 9%)Neurologic inv. (n=50, 19 %)Parenchymal inv. (n=37, 14%)Dural sinus thrombosis (n=13, 5%)Drug side effects other than infections (n=29, 15 %)Interferon (n=10, 5%)Azathioprine (n=7, 4%)Cyclosporine (n=5, 3%)Steroid (n=3, 2%)TNF antagonists (n=3, 2%)IVIG (n=1, 1%)GI inv. (n=18, 7%)Additional rheumatologic diseases (n=17, 9%)Joint inv. (n=12, 5%)Renal disease (n=16, 8 %)Mucocutaneous inv. (n=10, 4%)Cardiovascular dis. (n=12, 6%)Eye inv. (n=8, 3%)Avascular necrosis (n=4, 2%)Others (n=8, 3%)Malignancy (n=11, 6%)Others (n=40, 20%)*Some patients were hospitalized more than one times and for both BS related and non-BS related reasons at different time and had more than one type of BS related and/or non-BS related reasons.Disclosure of Interests:None declared

Objectives We are unaware of previous studies on hospitalisation in Behçet’s syndrome (BS). We surveyed the causes and outcome of hospitalisations among BS patients in a dedicated center. Methods We surveyed the records of all hospitalisations in our clinic between 2002-2011 to identify patients with a diagnosis of BS. We reviewed both the inpatient and outpatient charts of all BS patients who were hospitalised to identify the demographic and clinical features, causes of hospitalisation and outcome. We tried to contact the patients to determine their current condition. Results 178 BS patients (74% men, mean age 42.9±11.3) had been hospitalized for a total of 211 times during the last ten years. We were able to contact 104(58%) of them. The reasons for hospitalisation were directly related to BS organ involvement in 118(56%) and to complications in 93(44%). The most common BS related reasons were vascular involvement in 74/118(63%) (including 21 patients with pulmonary artery aneurysms, 10 with peripheral artery aneurysms and 11 with serious venous thrombosis such as vena cava superior and Budd-Chiari syndrome), neurologic involvement in 14/118(12%), gastrointestinal involvement in 6/118(5%) and eye involvement in 6/118(5%). Hospitalisations caused by complications of BS were infections in 39/93(42%), and other drug related adverse events in 15/93(16%). Neoplasias were diagnosed in 5 patients. Among the 178 patients, 16(9%) had died. Most common causes of death were vascular involvement (n=5), infections (n=4) and malignancies (n=4). Conclusions Vascular involvement is the leading cause of hospitalisation among BS patients, followed by infections related to therapy. Adverse events related to immunosuppressives are problematic. The predominance of men among hospitalized patients underlines the more severe course of BS in this sex. The relatively low frequency of gastrointestinal involvement among hospitalisations is in line with our previous observation that this type of involvement is rare in our BS patients. Disclosure of Interest None Declared

Background Gastrointestinal involvement can be a challenging complication of systemic vasculitis. It is a relatively common finding in polyarteritis nodosa and IgA realted vasculitis, an infrequent manifestation of ANCA associated vasculitis, and it can rarely manifest as a type of single organ vasculitis. Objectives To analyze the frequency and types of gastrointestinal (GI) involvement among our patients with systemic vasculitis and report the treatment modalities and outcome in these patients. Methods Clinical features of all patients with vasculitis who were hospitalized in our department have been prospectively recorded with a standard form between 2000 and 2010. Patients with Behçet's syndrome were not included since they are being recorded in a different database. We identified all vasculitis patients with GI involvement. Information regarding clinical, imaging and histological findings, treatment modalities and prognosis of these patients were obtained from patient charts. Patients who have not visited our department during the last 3 months were invited to the clinic for a final evaluation. Those who were not able to come were interviewed on the phone. Results A total of 236 patients were hospitalized in our clinic between 2000 and 2010 with a diagnosis of systemic vasculitis. Among these patients we identified 30 (13%) patients with GI involvement (mean age 40.2±17 years, 53% men, mean follow-up duration 56 (1–133) months). The main diagnoses were Takayasu arteritis (10/58, 17%), IgA related vasculitis (8/29, 27%), poliarteritis nodosa (6/20, 30%), GPA (Wegener's) (2/32, 6%) and others (4/97, 4%). The diagnosis of GI vasculitis was based on their having: mesenteric vascular (14/30), GI tract (18/30) and/or solid GI organ involvement (2/30). 12/30 patients had presented with either GI bleeding or perforations. Among those who had GI tract lesions, gastro-duodenal involvement was present in 4/18 and intestinal in 16/18. 8 patients (35%) were dead 31 months (1-96) after their diagnosis. The causes of death were gastrointestinal involvement in 4/8 patients (3 bleeding, 1 perforation). The other 4 patients had died due to infections. Seven patients were lost to follow-up and 15 patients were doing well. Conclusions GI involvement was present in 13% of our patients with systemic vasculitis on long term follow-up. Mortality and morbidity rates were considerably high. Mortality was either related to GI complications such as perforation and bleeding or infections associated with high dose immunosuppressives. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5970

No abstract